MS drug switch: does the body fight back?
NCT ID NCT05925049
Summary
This study aims to understand how often patients with relapsing-remitting multiple sclerosis (RRMS) develop antibodies against their treatment, natalizumab, when they switch from receiving it through an IV to a subcutaneous injection. It will observe about 400 patients in Europe, tracking if these antibodies are linked to serious side effects or MS relapses. The goal is to gather safety and effectiveness information about this new way of administering the drug.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Cambridge, Massachusetts, 02142, United States
Conditions
Explore the condition pages connected to this study.